Healthcare & Biotech

SHERIDAN, WYOMING – May 8, 2025 – B. Braun Group has demonstrated resilience and strategic growth amidst challenging global conditions, reporting a 4.4% increase in sales for the 2024 fiscal year. The company’s focus on innovation, operational efficiency, and modern technology investments has contributed to a solid financial performance, reaffirming its commitment to advancing healthcare solutions worldwide.

Robust Financial Growth and Increased Efficiency

In a year marked by rising costs and market volatility, B. Braun’s fiscal year 2024 results showcase the company’s ability to drive growth and improve profitability. The company’s sales surged to 9.1 billion euros, up from 8.8 billion euros the previous year. At constant exchange rates, this represents a notable 6.8% increase, aligning with B. Braun’s long-term growth target of 5-7%.

Key highlights from the 2024 fiscal year include:

SHERIDAN, WYOMING – May 8, 2025 – Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care, today revealed the successful outcome of all proposed resolutions at its 2025 Annual General Meeting (AGM). Among the significant decisions, shareholders approved key appointments to the Board, including the election of Deborah Di Sanzo, and granted approval for the 2024 Compensation Report and the Report on Non-Financial Matters.

Key Appointments and Re-elections

At the 2025 AGM, shareholders re-elected F. Michael Ball as Chair of the Board of Directors, alongside several other members who stood for re-election. This includes Lynn Bleil, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel, and Dieter Spälti. These appointments ensure the continued leadership and strategic direction of Alcon for the upcoming term.

SHERIDAN, WYOMING – May 8, 2025 – Alcon, the global leader in eye care, has announced its continued partnership with the Association for Research in Vision and Ophthalmology (ARVO) for the Eye Pitch live event, set to take place at the ARVO 2025 annual meeting in Salt Lake City, Utah, on May 3, 2025. This event will serve as a platform for entrepreneurs and researchers within the ophthalmic community to present groundbreaking ideas aimed at transforming eye care.

The Eye Pitch event allows ARVO members to pitch their innovative drug, device, or research proposals to a distinguished panel from both ARVO and the Alcon Seed Fund. The competition aims to spotlight early- and mid-stage innovations in the ophthalmic field, offering participants the chance to advance to the next phase of investment.

A Platform for Innovation

SHERIDAN, WYOMING – May 8, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today introduced the Elecsys® PRO-C3 test, a groundbreaking diagnostic solution designed to assess liver fibrosis severity in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). This innovative test, developed in partnership with Nordic Bioscience, provides healthcare providers with a fast and efficient way to evaluate liver fibrosis, a disease that contributes to one in every 25 deaths globally.

The Elecsys PRO-C3 test leverages Roche’s cobas® analyzers, delivering results in just 18 minutes, offering a swift and reliable diagnostic method. This new technology promises to significantly improve patient outcomes by enabling earlier identification of liver fibrosis, particularly in those affected by MASLD, and guiding timely treatment interventions.

SHERIDAN, WYOMING – May 8, 2025 – Roche has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an update to the European Union (EU) label for Phesgo®, a subcutaneous (SC) fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), used for treating HER2-positive breast cancer. The label update will allow for Phesgo to be administered outside of clinical settings, such as at patients’ homes, under the supervision of a healthcare professional.

This strategic recommendation marks a significant advancement in the delivery of cancer treatments, aligning with patient preferences and improving overall healthcare system efficiency. The move towards at-home administration is expected to reduce the strain on healthcare facilities and is expected to bring substantial cost savings for both patients and healthcare systems.

SHERIDAN, WYOMING – May 8, 2025 – Roche has achieved a significant milestone in oncology diagnostics with the U.S. Food and Drug Administration (FDA) granting Breakthrough Device Designation for its VENTANA® TROP2 (EPR20043) RxDx Device. This marks the first FDA recognition for a computational pathology companion diagnostic (CDx) device using artificial intelligence, highlighting Roche's continued leadership in cancer diagnostics and precision medicine.

The innovative VENTANA TROP2 RxDx device leverages AI to enhance diagnostic precision, improving the detection of non-small cell lung cancer (NSCLC) and enabling personalized treatment decisions. By utilizing cutting-edge digital pathology and AI-driven algorithms, Roche is setting a new standard for oncological diagnostics, advancing both the accuracy and speed of patient treatment strategies.

SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced that Marc N. Casper, the company’s chairman, president, and chief executive officer, will be presenting at the highly anticipated BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 11:40 a.m. (ET). The presentation will be available via a live webcast, accessible through the Investors section of Thermo Fisher’s official website.

SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced a significant $2 billion investment over the next four years, aimed at enhancing U.S. innovation and manufacturing across the life sciences sector. This strategic investment underscores Thermo Fisher's continued confidence in America's ability to lead global scientific advancement while further supporting biopharma companies in the development and production of life-saving medicines.

Strengthening U.S. Manufacturing Infrastructure

The bulk of the $2 billion investment, amounting to $1.5 billion, will be allocated toward expanding and upgrading Thermo Fisher’s U.S.-based manufacturing operations. This move not only solidifies the company's already strong presence in the U.S. but also positions it as a key player in maintaining a resilient healthcare supply chain.

SHERIDAN, WYOMING – May 08, 2025 – Agilent Technologies Inc. (NYSE: A) has introduced its highly anticipated Seahorse XF Flex Analyzer, an advanced, high-performance 24-well system designed to propel metabolic analysis in complex 3D tissue and organoid models. This groundbreaking tool, accompanied by dedicated consumables and kits, promises to transform the way researchers study cellular metabolism, providing critical insights into disease mechanisms and therapeutic development.

Enhancing Metabolic Research Capabilities

Metabolism plays a central role in cellular functions, powering energy production and processes like biosynthesis, mitochondrial function, and cell fate decisions. Disruptions in metabolism are linked to numerous diseases, making metabolic analysis a critical area of research. Traditionally, 2D models have been used for this purpose, but they often fail to reflect the complex biological interactions that occur in living organisms.

SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) is set to highlight its groundbreaking solutions and strategic collaborations at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, from April 25-30, 2025. Agilent’s innovative products, including advanced DNA cancer panels, multiomic profiling assays, and cutting-edge companion diagnostics, will take center stage, reflecting the company’s commitment to advancing cancer research and therapeutic development.